These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43 related articles for article (PubMed ID: 11032083)
1. Individualized, discrete event, simulations provide insight into inter- and intra-subject variability of extended-release, drug products. Kim SH; Jackson AJ; Hur R; Hunt CA Theor Biol Med Model; 2012 Aug; 9():39. PubMed ID: 22938185 [TBL] [Abstract][Full Text] [Related]
2. Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. I: conceptual and numerical issues. Popović J Eur J Drug Metab Pharmacokinet; 2006; 31(2):79-85. PubMed ID: 16898075 [TBL] [Abstract][Full Text] [Related]
3. The basis for individual bioequivalence. FDA Population and Individual Bioequivalence Working Group. Williams RL; Patnaik RN; Chen ML Eur J Drug Metab Pharmacokinet; 2000; 25(1):13-7. PubMed ID: 11032083 [No Abstract] [Full Text] [Related]
4. Some thoughts on individual bioequivalence. Liu J; Chow SC J Biopharm Stat; 1997 Mar; 7(1):41-8. PubMed ID: 9056587 [No Abstract] [Full Text] [Related]
5. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group. Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848 [TBL] [Abstract][Full Text] [Related]
6. A modified large sample approach in the assessment of population bioequivalence. Quiroz J; Ting N; Wei GC; Burdick RK J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391 [TBL] [Abstract][Full Text] [Related]
12. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Schuirmann DJ J Pharmacokinet Biopharm; 1987 Dec; 15(6):657-80. PubMed ID: 3450848 [TBL] [Abstract][Full Text] [Related]